
    
      The primary purpose of the study is to demonstrate the superiority of mesalazine granules
      compared to placebo in terms of the two primary efficacy variables 'proportion of
      recurrence-free patients within 48 weeks' and 'proportion of recurrence-free patients within
      96 weeks'.
    
  